Iodide Kinetics and Dosimetry In Vivo After Transfer of the Human Sodium Iodide Symporter Gene in Rat Thyroid Carcinoma Cells

Uwe Haberkorn, MD[1,2]; Petra Beuter[1,3]; Wolfgang Kübler, PhD[4]; Helmut Eskerski[2]; Michael Eisenhut, PhD[5]; Ralf Kinscherf, PhD[3]; Sabine Zitzmann, PhD[2]; Ludwig G. Strauss, MD[2]; Antonia Dimitrakopoulou-Strauss, MD[2]; and Annette Altmann, PhD[2]

[1]Department of Nuclear Medicine, University of Heidelberg, Heidelberg, Germany; [2]Clinical Cooperation Unit Nuclear Medicine, Deutsche Krebsforschungszentrum, Heidelberg, Germany; [3]Department of Anatomy and Cell Biology III, University of Heidelberg, Heidelberg, Germany; [4]Department of Radiation Protection, Deutsche Krebsforschungszentrum, Heidelberg, Germany; and [5]Department of Radiochemistry and Radiopharmacology, Deutsche Krebsforschungszentrum, Heidelberg, Germany

Transfer of the human sodium iodide symporter (hNIS) has been proposed as a new principle of cancer gene therapy. This study evaluates the iodide kinetics and dosimetry of iodide in hNIS-expressing thyroid carcinoma cells under optimized conditions. **Methods:** Using a bicistronic retroviral vector for the transfer of the hNIS and the hygromycin resistance gene, hNIS-expressing rat thyroid carcinoma cell lines were generated. Afterward, Na^{125}I uptake and efflux were determined in genetically modified and wild-type cells in the presence or absence of modulators of iodide transport. In addition, the ^{131}I distribution in thyroid-ablated nude mice bearing wild-type and genetically modified thyroid carcinomas was monitored after intraperitoneal administration of ^{131}I with and without coadministration of lithium carbonate. **Results:** hNIS-expressing cell lines accumulated up to 49 times more iodide than did noninfected cells, with a maximal iodide uptake after 30 min of incubation. However, a 90% efflux of the radioactivity occurred 20 min after replacement of the medium. In mice, the hNIS-expressing tumors accumulated up to 23 and 19.5 times more iodide than did the wild-type tumors in lithium-treated and control animals, respectively. However, efflux of the radioactivity was also observed in vivo: After 24 h, hNIS-expressing tumors lost 82.5% and 80.4% of the initial activity. Dosimetric calculations showed that 1,650 MBq of ^{131}I per square meter resulted in 5.4 and 5.2 Gy in hNIS-expressing tumors and 0.24 and 0.26 in wild-type tumors. **Conclusion:** Transduction of the hNIS gene in rat thyroid carcinoma cells induces iodide transport, which is associated with rapid efflux. Application of ^{131}I in clinically relevant amounts did not result in therapeutically useful absorbed doses in hNIS-expressing tumors in vivo, even under optimized conditions of thyroid ablation and treatment with lithium carbonate.

Key Words: sodium iodide symporter; gene therapy; lithium; thyroid carcinoma

J Nucl Med 2004; 45:827–833

Currently used viral vectors for gene therapy of cancer have a low infection efficiency leading to moderate or low therapy effects. This problem could be solved using an approach that leads to accumulation of radioactive isotopes with β-emission. In this case, isotope-trapping centers in the tumor could create a cross firing of β-particles, thereby efficiently killing transduced and nontransduced tumor cells.

Since the cloning of the human and rat complementary DNA sequences, several experimental studies have investigated iodide accumulation after recombinant expression of the human sodium iodide symporter (hNIS) gene in malignant tumors (*1–18*). Although initial uptake is high in the genetically modified tumors, differing results have been reported for the efficiency of radioiodine treatment based on hNIS gene transfer. These differences may be due to the different experimental protocols, such as whether thyroid ablation is used, the administration route of the tracer, the doses given to the animals, or the tumor and animal models used. To optimize the efficiency of radioiodide therapy, modulation of iodide kinetics has been applied. A higher accumulation in genetically modified tumors in animals after thyroid ablation has been described by Smit et al. (*16*). Furthermore, lithium has been used in vitro as well as in clinical studies to prolong iodide retention in tumor cells or in benign thyroid disease. This study combines thyroid ablation, intraperitoneal administration, and lithium treatment with transfer of the hNIS gene to assess iodide kinetics and dosimetry during radioiodine therapy under these optimized conditions.

MATERIALS AND METHODS

Retroviral Transfer of the hNIS Gene and Generation of Recombinant Cell Lines

For transfer of the hNIS gene, a bicistronic retroviral vector was used consisting of the hNIS gene and the hygromycin resistance

gene cloned downstream of the elongation factor 1α promoter. To ensure simultaneous expression of the genes coding for the hNIS and for the hygromycin resistance and stabilization of the messenger RNA, a synthetic intron and an internal ribosomal entry site from encephalomyocarditis virus was inserted between the genes (7,8). The rat papillary thyroid carcinoma cell line L2, which does not concentrate iodide ((19) obtained from Yoshio Hiasa, Nara, Japan), was maintained in Ham's F12 medium modified by addition of insulin (10 μg/mL), hydrocortisone (10 nU), transferrin (5 μg/mL), somatostatin (10 ng/mL), glycyl-histidyl-lysin (10 ng/mL), and 5% fetal calf serum. The transient packaging cell line BOSC23 used for the production of ecotropic retroviral particles was cultured in RPMI1640 medium (Gibco BRL) supplemented with glutamine (292 mg/L), penicillin (100,000 units/L), streptomycin (100 mg/L), and 10% fetal calf serum (20). The cell lines were cultured at 37°C, in an atmosphere of 95% air and 5% CO_2.

For transient packaging of the retroviral particles, a lipofection of BOSC23 cells was done. After 2 d, the medium was centrifuged to remove detached BOSC23 cells and used for the infection of L2 cells in the presence of 8 μg of polybrene per milliliter overnight. The cells were treated with hygromycin (425 μg/mL) for 4 wk until 13 resistant cell lines were established. These were used in iodide uptake experiments. The cell line that presented the maximal $^{125}I^-$ uptake (L2hNIShyg3) was used for the following experiments. The tumor doubling time in vitro was 15 ± 2.3 h for L2 and 14.5 ± 1.3 h for L2hNIShyg3.

Measurement and Modulation of ^{125}I Uptake and Efflux

Iodide uptake was determined in triplicates as described previously (7,21), and the experiments were repeated twice. In the presence of 74 kBq of $Na^{125}I$ (Amersham Buchler Germany; specific activity, 625.3 MBq/μg; radioactive concentration, 3.7 GBq/mL; radiochemical purity, 99.3%), the recombinant cell line L2hNIShyg3 and wild-type L2 cells were cultured for 1, 2, 5, 10, and 30 or 1, 2, and 4 h in 6 well plates. After being washed twice with ice-cold phosphate-buffered saline, the cells were lysed with sodium hydroxide on ice. With an automated NaI(Tl) well counter (Cobra II; Canberra Packard), the radioactivity was measured in cell lysates and in the medium. The viable cell number was determined in a Coulter counter (Coulter Electronics) and by trypan blue staining (more than 94% viable cells). The Coulter counter measured a median cell volume of 2.05 fL (range, 1.07–4.2 fL) for wild-type L2 cells and 1.96 fL (range, 1.11–4.05 fL).

For modulation of iodide uptake, hNIS-expressing and wild-type cells were incubated for 1 h in $Na^{125}I$ medium (74 kBq) or $Na^{125}I$ medium supplemented with sodium perchlorate (10 or 50 μmol/L; Sigma-Aldrich), ouabain (0.5 mmol/L), the anion channel blocker 4,4′-diisothiocyano-2,2′-disulfonic acid stilbene (DIDS, 100 or 300 μmol/L; Sigma-Aldrich), or the proton conductor carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP, 10 μmol/L; Sigma-Aldrich) according to Weiss et al. (21). Thereafter, the cells were washed, lysed, and counted as described.

To determine the $^{125}I^-$ efflux, recombinant and wild-type cells were incubated for 1 h in the presence or absence of 300 μmol of DIDS per liter, with medium containing 74 kBq of $Na^{125}I$ in 6 well plates. After the cells had been washed twice with phosphate-buffered saline, 3 wells were lysed immediately. To the other wells, fresh nonradioactive medium was added and the cells were again incubated for 2, 4, 6, 8, 10, 12, 16, or 20 min and washed and lysed as described.

Measurement of ^{131}I Uptake in Tumor Tissue of Nude Mice

The experiments were performed in compliance with German laws relating to the conduct of animal experimentation. Swiss CD1 nu/nu mice (Charles River Laboratories, delivered by Iffa Credo) weighing 20–25 g were first treated with 11 MBq (300 μCi) of ^{131}I given intraperitoneally to obtain thyroid ablation. Two weeks later, 2×10^6 tumor cells in 100 μL were transplanted subcutaneously into the right (L2hNIShyg3) or left (wild-type L2) thigh of the animals. At 4 wk after transplantation, 2 groups of animals were treated: group 1 ($n = 16$) received 0.5 mL of a physiologic sodium chloride solution intraperitoneally. One day later, 15 MBq (400 μCi) of ^{131}I, corresponding to a dose of 1,650 MBq/m² (calculated according to (8,22)), were given intraperitoneally together with a second dose of sodium chloride. Group 2 ($n = 16$) received lithium carbonate (370 mg/m²) in 0.5 mL of solution intraperitoneally on day 1. One day later, 15 MBq (400 μCi) of ^{131}I were given intraperitoneally together with lithium carbonate (185 mg/m²) in 0.5 mL of solution. The animals were sacrificed at 2, 6, 24, and 48 h after injection to analyze the absolute amount of radioactivity (percentage injected dose per gram of wet tissue) in tumors and other tissues using an automated NaI(Tl) well counter (Cobra II; Canberra Packard). MIRDOSE3* (23) was used to calculate the cumulated activity and the absorbed dose in wild-type and hNIS-expressing tumors after administration of 1,650 MBq/m². ^{131}I was calculated for a unit density sphere with a mass of 1 g, considering only the value of the absorbed dose in the sphere. Therefore, the sum of 2 exponential decay functions was fitted to the data points. The MIRDDOSE3* calculation of S-value for self-irradiation was 29.5 μGy/MBq·s.

For imaging studies performed with the animal under general gaseous anesthesia (40% O_2/60% N_2O/1% halothane) using a 25.4-cm (10 in.) scintillation camera (Searle-Siemens), only animals bearing tumors of a minimum of 15-mm diameter were accepted. The time-dependent relative accumulation of radioactivity in different regions of interest, such as the heart, liver, tumor, bladder, and whole animal, was monitored in 6 animals at 1, 2, 4, 8, and 24 h after injection.

The animal data were statistically analyzed by the t test, using SigmaPlot (version 8.0; Jandel Scientific).

RESULTS

Na^{125}I Uptake and Efflux in Wild-Type and Recombinant L2 Cell Lines

With respect to the wild-type counterparts, up to 49-fold more iodide was transported into the recombinant thyroid carcinoma cells. The initial uptake of iodide was dependent on the incubation time, and cells accumulated $^{125}I^-$ maximally after 10–30 min of incubation. The radioactivity measured after 1 and 4 h of $^{125}I^-$ incubation was at a plateau level, implicating steady-state uptake (Fig. 1).

Cell function was characterized by competition and efflux experiments. Figure 2 presents the effect of DIDS, FCCP, sodium perchlorate, and ouabain on $Na^{125}I$ uptake in the wild-type and the hNIS-expressing cells. In the presence of 10 or 50 μmol of sodium perchlorate per liter, we observed a dose-dependent inhibition of iodide accumulation—of 87% and 92%, respectively—in the L2hNIShyg3 cells. Ouabain caused a 75% inhibition, whereas addition of the

FIGURE 1. Time dependence of $^{125}I^-$ uptake in wild-type rat thyroid carcinoma cells and in the hNIS-expressing cell line L2hNIShyg3. Values are mean and SD ($n = 3$).

FIGURE 3. Iodide efflux from L2hNIShyg3 cells after 1 h of incubation with Na^{125}I with and without 300 µmol of DIDS per liter. Values are mean and SD ($n = 3$).

proton conductor FCCP led to a 75% loss of the accumulated I^-. The anion channel blocker DIDS had an opposite effect, with a 60% increase at a concentration of 300 µmol/L and a 18% decrease at a concentration of 100 µmol/L. In wild-type cells, 300 µmol of DIDS per liter caused an 86% increase at a low uptake level, whereas no changes occurred for the other modulators (Fig. 2).

To evaluate iodide efflux, we allowed ^{125}I uptake to proceed for 1 h, at which time a steady-state level of iodide accumulation was achieved. After the medium had been replaced by nonradioactive medium, the amount of $^{125}I^-$ present in the L2hNIShyg3 cell lysates was determined as a function of time. Up to 66% of the cellular radioactivity was released into the medium after 10 min, and 90% efflux was observed after 20 min (t$_{1/2}$ value of 5.8 min), indicating that the radiotracer was not trapped in the recombinant thyroid carcinoma cells (Fig. 3). The addition of a 300 µmol/L

concentration of DIDS to the culture led to an increased initial $^{125}I^-$ uptake; however, intracellular retention of the tracer was not prolonged, with 64% and 93% efflux at 10 and 20 min (t$_{1/2}$ value of 6.7 min), respectively.

$^{131}I^-$ Uptake in Tumor-Bearing Mice

To investigate iodide uptake in hNIS-expressing or -nonexpressing thyroid carcinoma in vivo, L2hNIShyg3 cells or wild-type L2 cells were transplanted into the right and left thighs of Swiss CD1 *nu/nu* mice. Consistent with the data obtained from the in vitro studies, hNIS-expressing tumor tissue significantly accumulated $^{131}I^-$, leading to scintigraphic visualization up to 24 h after tracer administration, whereas only low iodide uptake was observed in the wild-type thyroid carcinoma (Fig. 4). Because the animals received a thyroid ablative dose of $^{131}I^-$ before tumor cell transplantation, the thyroid was scintigraphically not visible. Tables 1 and 2 present the ex vivo quantitation of $^{131}I^-$ uptake per gram of tumor tissue, which was evaluated at different times after tracer administration. Except for the

**FIGURE 2.** Effect of DIDS, FCCP, sodium perchlorate (SP), and ouabain (ouab) on $^{125}I^-$ uptake in wild-type rat thyroid carcinoma cells and in the hNIS-expressing cell line L2hNIShyg3 after 1 h of incubation. Values are mean and SD ($n = 3$). con = control.


FIGURE 4. Scintigraphic images of tumor-bearing nude mice with subcutaneously transplanted hNIS-expressing (right thigh) or wild-type (left thigh) thyroid carcinoma cells at 2 h (A), 6 h (B), 24 h (C), and 48 h (D) after injection of $^{131}I^-$.

TABLE 1
Iodide Activity Concentration in Animals Treated with Lithium Carbonate at Different Times After Injection of ^{131}I

Tissue	Hours after injection			
	2	6	24	48
Brain	0.11 ± 0.009	0.09 ± 0.04	0.03 ± 0.01	0.005 ± 0.004
Stomach	8.79 ± 1.06	6.82 ± 2.96	2.82 ± 0.66	0.77 ± 0.62
Bowel	1.57 ± 0.29	0.91 ± 0.39	0.24 ± 0.05	0.013 ± 0.003
Liver	0.71 ± 0.13	0.47 ± 0.13	0.14 ± 0.02	0.014 ± 0.002
Spleen	0.84 ± 0.17	0.55 ± 0.18	0.15 ± 0.03	0.011 ± 0.003
Kidney	1.45 ± 0.31	0.78 ± 0.27	0.21 ± 0.03	0.012 ± 0.005
Muscle	0.54 ± 0.06	0.40 ± 0.19	0.08 ± 0.01	0.006 ± 0.002
Heart	1.00 ± 0.14	0.89 ± 0.48	0.15 ± 0.04	0.013 ± 0.008
Lung	1.40 ± 0.24	0.91 ± 0.27	0.25 ± 0.05	0.02 ± 0.007
Tumor weight	1.02 ± 0.31	0.62 ± 0.28	0.18 ± 0.03	0.02 ± 0.004
hNIS tumor weight	23.37 ± 4.90	17.05 ± 4.61	4.09 ± 0.38	0.52 ± 0.30

Values are mean and SD ($n = 4$) percentage injected dose per gram of tissue.

stomach (at 2 and 6 h after injection) iodide uptake was not statistically different in the organs and tumors after lithium carbonate or sodium chloride solution. Iodide accumulation was 23-fold (lithium treated) and 19.5-fold (sodium chloride) higher in hNIS-expressing tumor tissues than in wild-type tumor tissues. However, at 24 and 48 h after ^{131}I administration, only 4.09% and 0.52% of the injected dose per gram of tissue were found in the hNIS-expressing tumors after lithium administration and 4.22% and 0.35% after sodium chloride (0.18% and 0.02%, and 0.16% and 0.02%, respectively, for wild-type tumors; Tables 1 and 2). Therefore, an efflux of radioactivity from hNIS-expressing tumors was observed at 24 h after injection, with a loss of 82.5% and 80.4% of the initial activity in lithium-treated animals and control animals, respectively (Fig. 5). At 48 h after injection, 97.8% and 98.4% of the radioactivity were lost in these tumors. The intratumoral half-life of ^{131}I in hNIS-expressing tumors was 8.75 h in lithium-treated ani-

mals and 9.32 h in control animals. According to dosimetric calculations, 1,650 MBq/m^2 resulted in 5.2 and 5.4 Gy in animals after sodium chloride and lithium carbonate administration, respectively (wild-type tumor, 0.24 and 0.26 Gy, respectively).

DISCUSSION

Transfer of the hNIS gene has been suggested as a new therapeutic principle based on ^{131}I accumulation in malignant tumors. The hNIS gene has been transferred in a variety of tumor models using different vector systems and promoters and has resulted in a high initial uptake (*3–18*). Selective killing of hNIS-expressing cells has been observed in vitro using clonogenic assays, and a bystander effect has been suggested in 3-dimensional spheroid cultures (*3–5,9,11,13,17*). Furthermore, stably transfected human prostate carcinoma cells revealed a long biologic half-

TABLE 2
Iodide Activity Concentration in Animals Treated with Sodium Chloride at Different Times After Injection of ^{131}I

Tissue	Hours after injection			
	2	6	24	48
Brain	0.12 ± 0.01	0.11 ± 0.03	0.03 ± 0.02	0.001 ± 0.0004
Stomach	21.37 ± 2.26	11.32 ± 2.96	3.08 ± 1.25	0.32 ± 0.04
Bowel	1.24 ± 0.17	1.09 ± 0.39	0.21 ± 0.08	0.03 ± 0.003
Liver	0.83 ± 0.07	0.54 ± 0.13	0.12 ± 0.05	0.02 ± 0.002
Spleen	1.04 ± 0.04	0.68 ± 0.18	0.12 ± 0.04	0.02 ± 0.002
Kidney	1.52 ± 0.11	0.97 ± 0.27	0.20 ± 0.08	0.02 ± 0.003
Muscle	0.60 ± 0.08	0.45 ± 0.19	0.10 ± 0.04	0.02 ± 0.007
Heart	1.32 ± 0.18	0.67 ± 0.48	0.14 ± 0.05	0.04 ± 0.01
Lung	1.93 ± 0.12	1.08 ± 0.27	0.25 ± 0.10	0.03 ± 0.004
Tumor weight	1.16 ± 0.10	0.82 ± 0.50	0.16 ± 0.06	0.02 ± 0.002
hNIS tumor weight	21.48 ± 2.61	16.04 ± 4.61	4.22 ± 2.2	0.35 ± 0.006

Values are mean and SD ($n = 4$) percentage injected dose per gram of tissue.

FIGURE 5. $^{131}I^-$ uptake (kBq/g) in hNIS-expressing and wild-type thyroid carcinomas after administration of 1,650 MBq/m^2 at different times after radiotracer application in rats. Values are mean and SDs ($n = 4$).

life of 45 h in vivo, resulting in 84% tumor reduction after a single intraperitoneal application of a very high, 111-MBq, dose of ^{131}I (*17,18*).

However, no organification occurred, and despite initially high uptake, rapid efflux has been observed in different tumor models (*7,8,12,13,15,16,24*). Compared with uptake in the wild-type cell line, uptake in rat thyroid carcinomas was increased up to 49-fold, which is within the range of values reported for other models (*3,5,7,10*). Furthermore, a 90% efflux could be observed in vitro. The potent erythrocyte anion channel blocker DIDS increased initial uptake of iodide in the rat thyroid cell line FRTL5 but had no effect on the first component of iodide efflux, leading to the interpretation that the primary effect of DIDS is a stimulatory effect on iodide influx (*21*). Consequently, DIDS caused an increased initial $^{125}I^-$ uptake in the hNIS-expressing rat thyroid carcinoma cells; however, prolonged intracellular retention of the tracer was not achieved. Similar results have been obtained in other studies—in vitro as well as in vivo (*7,8,12,15,25*). Because the effectiveness of radioiodine therapy depends on the amount and biologic half-life of the isotope in the tumor, a therapeutically useful absorbed dose in vivo seems unlikely in these studies.

To optimize radioiodine therapy after hNIS gene transfer, we combined 3 different factors with a potential benefit concerning isotope retention in the tumor: thyroid ablation, intraperitoneal administration of ^{131}I, and treatment with lithium carbonate. Smit et al. have used thyroid ablation together with a low-iodine diet to increase iodide uptake in genetically modified tumors (*16*). Intraperitoneal or subcutaneous administration may result in prolonged retention in the animal because of prolonged resorption, which may partly explain the long half-life of iodide observed in former studies (*16–18*). In contrast to previously published data on Morris hepatoma or prostate carcinoma, the hNIS-expressing thyroid carcinomas in our study were clearly visible at 24 h after intraperitoneal tracer administration. Because the hNIS gene was under the control of a promoter independent of thyroid-stimulating hormone (TSH) (elongation factor 1α), the increased TSH levels caused by thyroid ablation were not likely to be influential.

Lithium has been reported to reduce iodine release from the thyroid and was therefore used to enhance radioiodine treatment of differentiated thyroid cancer (*26*). In FRTL-5 rat thyroid cells and in primary cultures of porcine thyroid follicles, lithium suppressed TSH-induced iodide uptake, iodide uptake stimulated by 8-bromo-cyclic adenosine monophosphate (cAMP), iodine organification, and de novo thyroid hormone formation (*27,28*). A variety of actions have been described for lithium, such as inhibition of adenosine triphosphatase activity, cAMP, intracellular enzymes, and inositol phospholipid metabolism, with an effect on signal transduction, and alteration of the in vitro response of cultured cells to thyrotropin-releasing hormone (*27–29*). Lithium is concentrated by the thyroid and inhibits thyroidal iodine uptake, iodotyrosine coupling, and thyroid hormone secretion and alters thyroglobulin structure (*27–31*). Therefore, if enhancement of iodide trapping in the thyroid by lithium relies on interaction with iodine coupling to tyrosine residues or inhibition of thyroid hormone secretion, an organification process is still needed for sufficient iodine to accumulate in the tumor.

Sieger et al. performed efflux experiments on hNIS-expressing hepatoma cells in the presence of different concentrations of lithium. Initial iodide uptake was higher in lithium-treated cells than in untreated cells when lithium concentrations of 2 and 10 mmol/L were used, but still, a 62% efflux was observed after 20 min. When lithium was used at a concentration of 50 mmol/L, the initial iodide uptake in treated cells decreased by 50% in comparison with untreated cells, with a 70% efflux after 20 min (*25*). We observed significant efflux in rat thyroid carcinoma in vivo: Only 4.09% ± 0.38% (lithium-treated animals) and 4.22% ± 2.2% (control animals) of the injected dose per gram in the hNIS-expressing tumors were observed at 24 h after tracer administration. At 48 h, these values were reduced to 0.52% ± 0.3% and 0.35% ± 0.006%, respectively. Similarly, Nakamoto et al. found that less than 1% of the injected radioactivity remained at 24 h after ^{131}I administration in modified MCF7 mammary carcinomas (*12*).

Our data corresponded to a very short half-life of ^{131}I (8.75 and 9.32 h in lithium-treated and control animals, respectively) in rat thyroid carcinomas. A short biologic half-life—3.6 h—has also been calculated by Nakamoto et al. for human mammary carcinomas (*12*). In contrast, differentiated thyroid carcinoma showed a biologic half-life of less than 10 d, and normal thyroid showed a biologic half-life of approximately 60 d (*32*). Therefore, whether radioiodine treatment is successful after transfer of the hNIS gene alone remains questionable. Consequently, dosimetric calculations showed that 1,650 MBq/m^2 resulted in 5.2 and 5.4 Gy in the hNIS-expressing rat thyroid carcinomas after

sodium chloride and lithium carbonate administration, respectively (in wild-type tumor, 0.24 and 0.26 Gy, respectively). Because approximately 80 Gy have been found necessary to eliminate metastases in patients with thyroid cancer, these levels are not likely to induce a significant therapeutic effect on tumors (33). Furthermore, the experiments were performed under ideal conditions, with 100% hNIS-expressing cells in the tumors. Given the low infection efficiency of current viral vectors in vivo, the absorbed dose in a clinical study would be considerably lower.

To prolong iodide retention, the thyroperoxidase gene was transferred either alone or in combination with the hNIS gene. However, a rapid efflux of iodide was observed, indicating no or very low thyroperoxidase activity (4,24,34). A further option to improve the outcome of therapy is the use of biologically more effective isotopes, as has been done using [188]Re-perrhenate or the high–linear-energy-transfer emitter [211]At (12,33,35). Although all radioisotopes showed rapid efflux, higher absorbed doses in the tumor were found for [211]At and [188]Re (33,35).

Compared with the experiments of Spitzweg et al. (16) and Smit et al. (17,18), this study differed in the administered dose and the animal models used. The 74- and 111-MBq doses used by Smit and Spitzweg correspond to administered doses of 11,100 and 16,650 MBq/m^2, respectively, in mice. These doses are far greater than doses used in patients. In our study, we used a dose that is in the range of doses administered to patients with differentiated thyroid carcinoma. Furthermore, Smit et al. injected ^{131}I at 3 wk after transplantation, when tumors were not visible. Small tumors may have a better chance to respond because they have no hypoperfused regions with limited tracer availability. However, this is not a realistic simulation of the tumor patient. There are also differences in the animal and tumor models and their biochemical properties that may lead to differences in iodide retention. The possibility also exists that a low-iodide diet benefits isotope accumulation in the tumor (16).

CONCLUSION

In conclusion, transfer of the sodium iodide transporter gene into rat thyroid adenocarcinoma cells, together with application of ^{131}I in clinically relevant amounts, did not result in therapeutically useful absorbed doses in hNIS-expressing tumors in vivo even under optimized conditions of thyroid ablation and treatment with lithium carbonate. Further studies have to examine pharmacologic modulation of iodide efflux or the use of the hNIS gene as an in vivo reporter gene (8,37–39).

ACKNOWLEDGMENTS

REFERENCES

1. Smanik PA, Liu Q, Furminger TL, et al. Cloning of the human sodium iodide symporter. *Biochem Biophys Res Commun.* 1996;226:339–345.
2. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. *Nature.* 1996;379:458–460.
3. Boland A, Ricard M, Opolon B, et al. Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. *Cancer Res.* 2000;60:3484–3492.
4. Boland A, Magnon C, Filetti S, et al. Transposition of the thyroid iodide uptake and organification system in nonthyroid tumor cells by adenoviral vector-mediated gene transfers. *Thyroid.* 2002;12:19–26.
5. Carlin S, Cunningham SH, Boyd M, McKlusky AG, Mairs RJ. Experimental targeted radioiodide therapy following transfection of the sodium iodide symporter gene: effect on clonogenicity in both two- and three-dimensional models. *Cancer Gene Ther.* 2000;7:1529–1536.
6. Cho JY, Xing S, Liu X, et al. Expression and activity of human Na+/I− symporter in human glioma cells by adenovirus-mediated gene delivery. *Gene Ther.* 2000;7:740–749.
7. Haberkorn U, Henze M, Altmann A, et al. Transfer of the human sodium iodide symporter gene enhances iodide uptake in hepatoma cells. *J Nucl Med.* 2001;42:317–325.
8. Haberkorn U, Kinscherf R, Kissel M, et al. Enhanced iodide transport after transfer of the human sodium iodide symporter gene is associated with lack of retention and low absorbed dose. *Gene Ther.* 2003;10:774–780.
9. Heltemes LM, Hagan CR, Mitrofanova EE, Panchal RG, Guo J, Link CJ. The rat sodium iodide symporter gene permits more effective radioisotope concentration than the human sodium iodide symporter gene in human and rodent cancer cells. *Cancer Gene Ther.* 2003;10:14–22.
10. La Perle KMD, Shen D, Buckwalter TLF, et al. In vivo expression and function of the sodium iodide symporter following gene transfer in the MATLyLu rat model of metastatic prostate cancer. *Prostate.* 2002;50:170–178.
11. Mandell RB, Mandell LZ, Link CJ. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. *Cancer Res.* 1999;59:661–668.
12. Nakamoto Y, Saga T, Misaki T, et al. Establishment and characterization of a breast cancer cell line expressing Na+/I− symporters for radioiodide concentrator gene therapy. *J Nucl Med.* 2000;41:1898–1904.
13. Schipper ML, Weber A, Behe M, et al. Radioiodide treatment after sodium iodide symporter gene transfer is a highly effective therapy in neuroendocrine tumor cells. *Cancer Res.* 2003;63:1333–1338.
14. Shimura H, Haraguchi K, Miyazaki A, Endo T, Onaya T. Iodide uptake and experimental ^{131}I therapy in transplanted undifferentiated thyroid cancer cells expressing the Na+/I− symporter gene. *Endocrinology.* 1997;138:4493–4496.
15. Smit JW, Shroder van der Elst JP, Karperien M, et al. Reestablishment of in vitro and in vivo iodide uptake by transfection of the human sodium iodide symporter (hNIS) in a hNIS defective human thyroid carcinoma cell line. *Thyroid.* 2000;10:939–943.
16. Smit JWA, Schroeder van der Elst JP, Karperien M, et al. Iodide kinetics and experimental ^{131}I therapy in a xenotransplanted human sodium-iodide symporter-transfected human follicular thyroid carcinoma cell line. *J Clin Endocrinol Metab.* 2002;87:1247–1253.
17. Spitzweg C, O'Connor MK, Bergert ER, Tindall DJ, Young CY, Morris JC. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. *Cancer Res.* 2000;60:6526–6530.
18. Spitzweg C, Dietz AB, O'Connor MK, et al. In vivo sodium iodide symporter gene therapy of prostate cancer. *Gene Ther.* 2001;8:1524–1531.
19. Hiasa Y, Kitahori Y, Yane K, et al. Establishment of estrogen receptor-positive transplantable rat thyroid tumor cell lines in vivo. *Cancer Res.* 1993;53:4408–4412.
20. Pear WS, Nolan GP, Scott ML, Baltimorre D. Production of high titer helper-free retroviruses by transient transfection. *Proc Natl Acad Sci USA.* 1993;90:8392–8396.
21. Weiss SJ, Philp NJ, Grollman EF. Iodide transport in a continuous line of cultured cells from rat thyroid. *Endocrinology.* 1984;114:1090–1098.
22. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. *Cancer Chemother Rep.* 1966;50:219–244.
23. Stabin M. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. *J Nucl Med.* 1996;37:538–546.
24. Huang M, Batra RK, Kogai T, et al. Ectopic expression of the thyroperoxidase gene augments radioiodide uptake and retention mediated by the sodium iodide symporter in non-small cell lung cancer. *Cancer Gene Ther.* 2001;8:612–618.
25. Sieger S, Shiming J, Schönsiegel F, Altmann A, Kübler W, Haberkorn U. Tumour specific activation of the sodium/iodide symporter gene under control of

the glucose transporter gene 1 promoter (GTI-1.3). *Eur J Nucl Med.* 2003;30: 748–756.

26. Koong S, Reynolds JC, Movius EG, et al. Lithium as a potential adjuvant to ^{131}I therapy of metastatic, well differentiated thyroid carcinoma. *J Clin Endocrinol Metab.* 1999;84:912–916.

27. Urabe M, Hershman JM, Pang XP, Murakami S, Sugawara M. Effect of lithium on function and growth of thyroid cells in vitro. *Endocrinology.* 1991;129:807–814.

28. Lazarus JH. The effects of lithium therapy on thyroid and thyrotropin-releasing hormone. *Thyroid.* 1998;8:909–913.

29. Sedvall G, Jonsson B, Petterson U, Levin K. Effects of lithium salts on plasma protein bound iodine and uptake of ^{131}I in thyroid gland of man and rat. *Life Sci.* 1968;7:1257–1264.

30. Temple R, Berman M, Robbins J, Wolff J. The use of lithium in the treatment of thyrotoxicosis. *J Clin Invest.* 1972;51:2746–2756.

31. Gershengorn MC, Izumi M, Robbins J. Use of lithium as an adjunct to radioiodine therapy of thyroid carcinoma. *J Clin Endocrinol Metab.* 1976;42:105–111.

32. Berman M, Hoff E, Barandes M. Iodine kinetics in man: a model. *J Clin Endocrinol Metab.* 1968;28:1–14.

33. Maxon HR, Thomas SR, Herzberg VS, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. *N Engl J Med.* 1983;309:937–941.

34. Haberkorn U, Altmann A, Jiang S, Morr I, Mahmut M, Eisenhut M. Iodide uptake in human anaplastic thyroid carcinoma cells after transfer of the human thyroid peroxidase gene. *Eur J Nucl Med.* 2001;28:633–638.

35. Dadachova E, Bouzahzah B, Zuckier LS, Pestell RG. Rhenium-188 as an alternative to iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS). *Nucl Med Biol.* 2002;29:13–18.

36. Petrich T, Helmeke HJ, Meyer GJ, Knapp WH, Potter E. Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium iodide symporter. *Eur J Nucl Med.* 2002;29:842–854.

37. Haberkorn U, Altmann A, Eisenhut M. Functional genomics and proteomics: the role of nuclear medicine. *Eur J Nucl Med.* 2002;29:115–132.

38. Chung JK. Sodium iodide symporter: its role in nuclear medicine. *J Nucl Med.* 2002;43:1188–1200.

39. Groot Wassink T, Aboagye EO, Glaser M, Lemoine NR, Vassaux G. Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium iodide symporter as reporter gene. *Hum Gene Ther.* 2002;13:1723–1735.